Reference Message Network reported on May 30 according to a report by the Spanish "Economist" website on May 26, the acquisition of Chinese new drugs or pharmaceutical companies by foreign pharmaceutical enterprises, especially those from Europe and the United States, is a clear and constantly growing trend. According to the "Global R&D Trends Report for 2025" released by the U.S. healthcare consulting company Quintiles IMS, in 2024, European and American pharmaceutical companies reached 71 acquisition agreements with entities in this Asian country, an increase of 37% compared to the number four years ago (52 acquisition agreements). The report states that European and American pharmaceutical companies are seeking to obtain China's medical innovation results and assets. For many years, the number of European and American pharmaceutical companies acquiring Chinese new drugs or pharmaceutical companies has generally been increasing. In terms of acquiring Chinese pharmaceutical companies, Beyer Company acquired Primes Biotechnology Co., Ltd. for $836.9 million. Through this deal, Beyer added a new drug for treating lung cancer and breast cancer to its product portfolio. Johnson & Johnson acquired Proteologix for approximately $800 million, whose business focus is on developing drugs for treating immune-mediated diseases. Additionally, Novartis acquired Cendrillon Medicine, which focuses on researching treatments for kidney diseases. In terms of acquiring Chinese new drugs, AbbVie signed an agreement with Mingji BioPharmaceutical to develop a new therapy for inflammatory bowel disease. Furthermore, after obtaining approval from relevant authorities, AbbVie will be responsible for the production and marketing of the drug for this therapy. The report points out that at the same time, the number of Asian pharmaceutical companies acquiring European and American drugs or pharmaceutical companies has been declining in recent years. The report from Quintiles IMS shows that in 2024, the number of acquisition agreements between Asian pharmaceutical companies and European and American pharmaceuticals or pharmaceutical companies decreased by about 75% compared to 2020. In terms of research and development, three out of every ten clinical trials starting in 2024 are undertaken by Chinese pharmaceutical companies. Specifically, Chinese pharmaceutical companies lead 1669 clinical studies. This level is close to the proportion of global clinical trials conducted by U.S. pharmaceutical companies (approximately 35%). The report from Quintiles IMS states: "The large number of studies led by Chinese pharmaceutical companies makes the country one of the leading players in the global clinical trial field." From the perspective of treatment areas, Chinese pharmaceutical companies participate in 33% of the world's new drug development for infectious diseases and 39% for oncology. [Photograph: A staff member checks the inner packaging of peritoneal dialysis solution in the peritoneal dialysis solution workshop of a pharmaceutical company in Rizhao, Shandong.] Original article: https://www.toutiao.com/article/7510127590267421199/ Disclaimer: This article only represents the views of the author. Welcome to express your attitude by clicking the "Like/Dislike" buttons below.